The efficacy and functions of dasatinib tablets

Dasatinib tablets are an anti-tumor drug whose efficacy and role are mainly reflected in the treatment of specific types of leukemia.

Dasatinib tablets are mainly used to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) patients who are resistant or intolerant to imatinib mesylate, including adult patients in the chronic phase, accelerated phase and blast phase (blast myeloblastosis and blast phase). It is another new option for patients with poor clinical efficacy after developing resistance to imatinib.

Dasatinib is a protein kinase inhibitor that can inhibit a variety of oncogenic kinases, including Bcr-Abl fusion protein, Src family kinases, etc., thereby inhibiting the proliferation and activity of leukemia cells. It controls cell division and affects cell proliferation by blocking the activity of cyclin-dependent kinases, thereby achieving therapeutic purposes.

During the treatment process, dasatinib tablets can not only inhibit the proliferation of leukemia cells, but also enhance physical fitness to a certain extent and improve the patient's quality of life. This is of great significance to leukemia patients receiving long-term treatment.

For CML patients who are resistant or intolerant to imatinib mesylate, dasatinib tablets can provide a new treatment option, which can help delay the progression of the disease and prolong the patient's survival.

Bcr-Ablfusion protein is one of the key molecular mechanisms of CML pathogenesis. Dasatinib can specifically inhibit the function of Bcr-Abl fusion protein and restore normal cell signaling, thus inhibiting the proliferation of leukemia cells. Src family kinases are involved in cell signal transduction and inflammatory response, and are associated with a variety of diseases. Dasatinib further blocks the signaling pathway of leukemia cells and inhibits their proliferation and activity by inhibiting the activity of Src family kinases.

ExceptBcr-AblandSrcIn addition to family kinases, dasatinib can also inhibit cyclin-dependent kinases and Eph receptors. These kinases play important roles in cell proliferation, differentiation and other biological processes. Dasatinib inhibits the activity of these kinases through multiple pathways and comprehensively inhibits the proliferation of leukemia cells.

The recommended dose for patients with chronic myelogenous leukemia in the chronic phase is 100mg, 1 times a day; the dose can be adjusted to 140mg, 1 times a day based on patient response and tolerance. For patients with advanced or Ph chromosome-positive acute lymphoblastic leukemia, the initial dose is 70mg twice a day; it can be adjusted to 100mg twice a day as needed. The time of administration should be consistent, either in the morning or in the evening. It can be taken before or after meals. If gastrointestinal discomfort occurs, it can be taken with meals.

This product is contraindicated in patients who are allergic to dasatinib or any excipient. There is currently no clinical research data on the use of dasatinib tablets in pregnant and lactating women, so its use is not recommended for pregnant and lactating women. If used by lactating women, breastfeeding should be discontinued during treatment.

This product should be used with caution in patients with liver damage, and the dose needs to be adjusted if necessary. While taking dasatinib, the patient's blood routine, electrocardiogram, biochemistry, chest X-ray and other indicators, as well as changes in the Philadelphia chromosome and bcr-abl fusion gene, should be closely monitored to evaluate the therapeutic effect and safety. Dasatinib may interact with a variety of drugs, such as acetaminophen, antacids, proton pump inhibitors, etc. Therefore, if you need to use other drugs while taking this product, you should consult your doctor first.